Get the Stockscreener App
6.60
3.65%
-0.25
Mersana Therapeutics Inc stock is traded at $6.60, with a volume of 110.56K.
It is down -3.65% in the last 24 hours and down -5.38% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$6.85
Open:
$6.66
24h Volume:
110.56K
Relative Volume:
0.93
Market Cap:
$34.15M
Revenue:
$36.86M
Net Income/Loss:
$-171.67M
P/E Ratio:
-4.40
EPS:
-1.5
Net Cash Flow:
$-171.05M
1W Performance:
-14.29%
1M Performance:
-5.38%
6M Performance:
-56.64%
1Y Performance:
-85.33%
1-Day Range:
$6.37
$6.8005
1-Week Range:
$6.37
$7.60
52-Week Range:
$6.37
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
6.60 | 34.15M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
How does Mersana Therapeutics Inc. compare to its industry peersWealth Building Review With Proven Results - jammulinksnews.com
What are analysts’ price targets for Mersana Therapeutics Inc. in the next 12 monthsAI Powered Target Finder For Consistent Profits - jammulinksnews.com
What is the dividend policy of Mersana Therapeutics Inc. stockRetirement Planning Insights For 2025 - jammulinksnews.com
How strong is Mersana Therapeutics Inc. company’s balance sheetStock Strategy Insights For Fast Growth - jammulinksnews.com
How Mersana Therapeutics Inc. stock performs during market volatilityShort Term Alpha Signals Review - beatles.ru
Will Mersana Therapeutics Inc. benefit from macro trendsGrowth Based Investment Plan Guidance Highlighted - metal.it
Published on: 2025-07-30 03:04:39 - metal.it
Published on: 2025-07-29 23:14:19 - metal.it
Will Mersana Therapeutics Inc. stock split in the near futureBreakout Stocks Insights To Watch Now - jammulinksnews.com
Is Mersana Therapeutics Inc. a Top Dividend Stock to Watch in 2025Watchlist for Low Risk High Return Stocks Updated - metal.it
Top Risks to Consider Before Buying Mersana Therapeutics Inc. Stock Oversold Reversal Picks with Buy Zone - metal.it
What are the latest earnings results for Mersana Therapeutics Inc.Skyrocketing investment returns - jammulinksnews.com
What is Mersana Therapeutics Inc. company’s growth strategyUnmatched market performance - jammulinksnews.com
Does Mersana Therapeutics Inc. stock perform well during market downturnsBreakthrough capital growth - jammulinksnews.com
Should I hold or sell Mersana Therapeutics Inc. stock in 2025Exceptional stock performance - jammulinksnews.com
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - metal.it
How does Mersana Therapeutics Inc. generate profit in a changing economyDiscover undervalued stocks ready to soar - jammulinksnews.com
MRSN Trading Halted Due to Pending News - GuruFocus
What analysts say about Mersana Therapeutics Inc. stockSuperior stock selection - PrintWeekIndia
Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025 - Insider Monkey
What drives Mersana Therapeutics Inc. stock priceRapid wealth accumulation - PrintWeekIndia
Mersana Therapeutics to execute 1-for-25 reverse stock split - MSN
Mersana To Implement 1-for-25 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq
Mersana Therapeutics Implements Reverse Stock Split to Meet Nasdaq Listing Requirements - AInvest
Mersana Therapeutics Plunges 19.4%, Reverse Split Ignites Market Volatility: What’s Fueling the Panic? - AInvest
Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan - Investing.com Australia
Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan By Investing.com - Investing.com South Africa
Mersana Therapeutics to implement 1-for-25 reverse stock split Friday - Investing.com Australia
Mersana Therapeutics to implement 1-for-25 reverse stock split Friday By Investing.com - Investing.com South Africa
Mersana Therapeutics (MRSN) Implements 1-for-25 Reverse Stock Sp - GuruFocus
Mersana Therapeutics Announces Reverse Stock Split - TipRanks
Mersana Therapeutics to implement 1-for-25 reverse stock split By Investing.com - Investing.com India
Mersana Therapeutics to implement 1-for-25 reverse stock split - Investing.com Australia
Mersana (MRSN) Announces 1-for-25 Reverse Split to Retain Nasdaq Listing - Stock Titan
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewswire
Mersana's 1:25 Reverse Split Aims to Save Nasdaq Listing: Key Details for Investors - Stock Titan
Mersana Therapeutics Inc. Stock Analysis and ForecastSuperior stock growth - Autocar Professional
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):